妊娠期每周一次利福喷丁联合异烟肼3个月方案预防结核的药代动力学与安全性
IMPAACT 2001是一项I/II期试验,在50名有结核预防指征的孕妇中评估每周一次利福喷丁联合异烟肼(3HP)的药代动力学与安全性。结果显示3HP无需在妊娠期调整剂量,尽管HIV感染者利福喷丁清除率较高,但所有女性均达到与成功预防结核相关的暴露水平,未发生药物相关严重不良事件。
要点
- 妊娠期使用3HP方案无需调整剂量。
- HIV感染者利福喷丁清除率较无HIV者高30%,但暴露仍达标。
- 未观察到药物相关严重不良事件、治疗中断或结核病例。
核心结论
- 3HP方案在妊娠期无需调整剂量。
- 所有孕妇均达到与成功预防结核相关的利福喷丁和异烟肼暴露。
- 数据支持开展更大规模的安全性研究。
研究设计与样本
- IMPAACT 2001为I/II期试验,在海地、肯尼亚、马拉维、泰国和津巴布韦开展。
- 纳入50名有结核预防指征的孕妇,其中20名HIV感染者正在接受基于依非韦伦的抗逆转录病毒治疗。
- 异烟肼和利福喷丁按标准剂量(900 mg/周)给药,在第一剂(第二/三孕期)和第十二剂(第三孕期/产后)进行药代动力学采样。
- 采用非线性混合效应模型估计药物群体药代动力学。
主要发现
- 无HIV的孕妇中,利福喷丁清除率妊娠期较产后低28%(1.20 vs 1.53 L/小时,P < .001),AUCSS分别为786和673 mg × 小时/L。
- HIV感染孕妇的利福喷丁清除率较无HIV孕妇高30%(P < .001),导致AUCSS较低(522 mg × 小时/L);妊娠期与产后清除率无显著变化。
- 妊娠未影响异烟肼药代动力学。
- 未发生药物相关严重不良事件、治疗中断或女性及婴儿结核病例。
关键数值与推荐
- 利福喷丁标准剂量为900 mg/周。
- 无HIV孕妇妊娠期利福喷丁清除率1.20 L/小时,产后1.53 L/小时(P < .001)。
- HIV感染孕妇利福喷丁AUCSS为522 mg × 小时/L。
临床怎么用
- 妊娠期有结核预防指征者可考虑使用3HP方案,无需调整剂量。
- HIV感染孕妇使用3HP时利福喷丁暴露较低,但仍达到有效暴露水平。
局限性
- 样本量较小(50例)。
- 需更大规模的安全性研究进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pregnancy increases the risk of tuberculosis and its complications. A 3-month regimen of weekly isoniazid and rifapentine (3HP) is safe and effective for tuberculosis prevention in adults and children, including those with HIV, but 3HP has not been evaluated in pregnancy. METHODS: IMPAACT 2001 was a phase I/II trial evaluating the pharmacokinetics and safety of 3HP among pregnant women with indications for tuberculosis preventative therapy in Haiti, Kenya, Malawi, Thailand, and Zimbabwe (NCT02651259). Isoniazid and rifapentine were provided at standard doses (900 mg/week). Pharmacokinetic sampling was performed with the first (second/third trimester) and twelfth (third trimester/postpartum) doses. Nonlinear mixed-effects models were used to estimate drug population pharmacokinetics. RESULTS: Of 50 participants, 20 had HIV and were taking efavirenz-based antiretroviral therapy. Among women without HIV, clearance of rifapentine was 28% lower during pregnancy than postpartum (1.20 vs 1.53 L/hour, P < .001), with area under the concentration-time curve (AUCSS) of 786 and 673 mg × hour/L, respectively. In pregnant women with HIV, clearance was 30% higher than women without HIV (P < .001), resulting in lower AUCss (522 mg × hour/L); clearance did not change significantly between pregnancy and postpartum. Pregnancy did not impact isoniazid pharmacokinetics. There were no drug-related serious adverse events, treatment discontinuations, or tuberculosis cases in women or infants. CONCLUSIONS: 3HP does not require dose adjustment in pregnancy. Rifapentine clearance is higher among women with HIV, but all women achieved exposures of rifapentine and isoniazid associated with successful tuberculosis prevention. The data support proceeding with larger safety-focused studies of 3HP in pregnancy. CLINICAL TRIALS REGISTRATION: ClinicalTrials.gov, NCT02651259.
引用
- Mathad JS, Savic R, Britto P, et al. Pharmacokinetics and Safety of 3 Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women. Clin Infect Dis. 2022. PMID: 34323955. doi:10.1093/cid/ciab665
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。